[1]Rusnak DW,et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther.1(2):85-94(2001).
[2]Nelson MH,et al. A review of lapatinibditosylate in the treatment of refractory or advanced
breast cancer.Ther Clin Risk Manag. 3(4):665-73(2007).
[3]Chu I, et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res.65(1):18-25(2005).